Hyperliquid Strategies Inc
Close on Oct 19, 2026
- Market cap
- $1.40B
- P/E (TTM)
- 2.8
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2026 Ended Jun 30, 2026 | Aug 27, 2026 | Before market open | – | – | – |
| Q3 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | $2.60M | – | – |
| Q2 FY2026 Ended Dec 31, 2025 | Feb 11, 2026 | Before market open | – | – | – |
Press releases
Announcements Hyperliquid Strategies filed with the SEC
Hyperliquid Strategies Inc Reports Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
AUGUST 27, 2026 Fiscal Year 2026 Earnings Review
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Hyperliquid Strategies Inc Reports Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Third Quarter Earnings Review | May 7, 2026 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Hyperliquid Strategies Inc Reports Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q4 2025 Financial Results | February 11, 2026 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Hyperliquid Strategies Inc Announces $30 million Stock Repurchase Program
Regulation FD disclosure · EX-99.1 to Form 8-K
Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K